Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Bernd, Liedert"'
Autor:
Edward S. Kim, MD, Sigrid Balser, PhD, Klaus B. Rohr, PhD, Ragna Lohmann, PhD, Bernd Liedert, PhD, Dorothee Schliephake, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100248- (2022)
Introduction: Biological therapies such as bevacizumab have improved survival in patients with NSCLC. This study was conducted to confirm the equivalent efficacy of the biosimilar candidate BI 695502 to the bevacizumab reference product (RP). Methods
Externí odkaz:
https://doaj.org/article/8aa29ceaae964afeb78c42ab102398ac
Autor:
Sigrid Balser, Ekkehard Brockstedt, Stefan Schreiber, Viktoria Moschetti, Bernd Liedert, Stephen B. Hanauer
Publikováno v:
The Lancet Gastroenterology & Hepatology. 6:816-825
BI 695501 is a biosimilar that has demonstrated similar efficacy, safety, and immunogenicity to adalimumab reference product in patients with rheumatoid arthritis and chronic plaque psoriasis. The VOLTAIRE-CD study aimed to compare the efficacy and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92872a9317d2fcd507e45d5ce27f6b0e
https://doi.org/10.1016/s2468-1253(21)00252-1
https://doi.org/10.1016/s2468-1253(21)00252-1
Autor:
Tanios S Bekaii-Saab, Sigrid Balser, Ragna Lohmann, Hasan Daoud, Bernd Liedert, Dorothee Schliephake
Publikováno v:
Colorectal Cancer.
Aim: This study assessed the safety, efficacy, pharmacokinetics and immunogenicity of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in patients with metastatic colorectal cancer (mCRC). Materials & methods: Patients with untreated mCRC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b12f47e11e6a152be53013a29717937
https://doi.org/10.2217/crc-2022-0002
https://doi.org/10.2217/crc-2022-0002
Autor:
Bernhard Hemmer, Heinz Wiendl, Karsten Roth, Hendrik Wessels, Josef Höfler, Cyrill Hornuss, Bernd Liedert, Krzysztof Selmaj
Publikováno v:
JAMA Neurology. 80:298
ImportanceProposed biosimilar natalizumab (biosim-NTZ) PB006 is the first biosimilar monoclonal antibody therapy developed for multiple sclerosis (MS) treatment.ObjectiveTo evaluate matching efficacy, safety, and immunogenicity between biosim-NTZ and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56d6639370b2dd3ae3b906e3c2e705fd
https://doi.org/10.1001/jamaneurol.2022.5007
https://doi.org/10.1001/jamaneurol.2022.5007
Autor:
Bernd Liedert, Edward S. Kim, Sigrid Balser, Klaus B Rohr, Dorothee Schliephake, Ragna Lohmann
Publikováno v:
JTO Clinical and Research Reports
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100248-(2022)
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100248-(2022)
INTRODUCTION Biological therapies such as bevacizumab have improved survival in patients with non-small-cell lung cancer (NSCLC). This study was conducted to confirm equivalent efficacy of the biosimilar candidate BI 695502 to bevacizumab reference p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b553e35871d44dd972c5b239b9d791f2
http://europepmc.org/articles/PMC8713120
http://europepmc.org/articles/PMC8713120
Autor:
Thijs van Iersel, Bernd Liedert, Steven Ramael, Ivo Sonderegger, Viktoria Moschetti, Benjamin Van Hoorick, Renger Tiessen, Sabrina Wiebe, Girish Jayadeva, Benjamin Lang
Publikováno v:
Rheumatology and Therapy. 5:403-421
BI 695501 has shown similar efficacy, safety, and immunogenicity to the adalimumab reference product, Humira®. We present two phase 1 studies comparing the pharmacokinetics, safety, and immunogenicity of BI 695501 delivered via autoinjector (AI) vs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8785abbbded17f06e957ac28a2cb6cfc
https://doi.org/10.1007/s40744-018-0119-1
https://doi.org/10.1007/s40744-018-0119-1
Publikováno v:
American Journal of Gastroenterology. 114:S13-S14
BACKGROUND:BI 695501 has demonstrated bioequivalence to both the US-licensed and EU-approved adalimumab reference product (RP) in rheumatoid arthritis. The aim of this head-to-head trial was to evaluate the similarity of BI 695501 and EU-approved ada
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89f7330bbb4e9eb79407ee6aacd3a55f
https://doi.org/10.14309/01.ajg.0000613176.48811.7c
https://doi.org/10.14309/01.ajg.0000613176.48811.7c
Autor:
Sigrid Balser, Viktoria Moschetti, Stefan Schreiber, Ekkehard Brockstedt, Bernd Liedert, Stephen B. Hanauer
Publikováno v:
Gastroenterology. 158:S-1192
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::860ada4f84fc27900cb88e005f41b501
https://doi.org/10.1016/s0016-5085(20)33649-0
https://doi.org/10.1016/s0016-5085(20)33649-0
Autor:
Steven, Ramael, Benjamin, Van Hoorick, Renger, Tiessen, Thijs, van Iersel, Viktoria, Moschetti, Benjamin, Lang, Ivo, Sonderegger, Sabrina, Wiebe, Bernd, Liedert, Girish, Jayadeva
Publikováno v:
Rheumatology and Therapy
Introduction BI 695501 has shown similar efficacy, safety, and immunogenicity to the adalimumab reference product, Humira®. We present two phase 1 studies comparing the pharmacokinetics, safety, and immunogenicity of BI 695501 delivered via autoinje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7592e489a89bd9d22ef4e952d2009d3c
https://pubmed.ncbi.nlm.nih.gov/29959660
https://pubmed.ncbi.nlm.nih.gov/29959660
Publikováno v:
Abstracts Accepted for Publication.
Background PK bioequivalence of BI 695501, an adalimumab biosimilar candidate, and the adalimumab originator was demonstrated previously (VOLTAIRE®-PK: Wynne et al., Expert Opin Investig Drugs 2016;25:1361–70). Administration in chronic inflammato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b0766d9f52f9b4e5716815e6fc0b82c
https://doi.org/10.1136/annrheumdis-2017-eular.3507
https://doi.org/10.1136/annrheumdis-2017-eular.3507